Alison Luckey

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study

Oliver A. Cornely, José Miguel Cisneros, Julián Torre‐Cisneros et al. · Journal of Antimicrobial Chemotherapy · 2019 · 123 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial

Yehuda Carmeli, José Miguel Cisneros, Mical Paul et al. · The Lancet Infectious Diseases · 2024 · 102 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation

Shampa Das, Todd Riccobene, Timothy J. Carrothers et al. · European Journal of Clinical Pharmacology · 2024 · 29 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17